Observational studyBMC endocrine disorders2026
Real-world insights into empagliflozin use in heart failure across ejection fractions and patients with or without diabetes: a multicenter study from Bangladesh.
Observational study in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmpagliflozin, a member of the Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor family, is a promising antidiabetic drug with proven benefits in heart failure (HF). However, its effects in heart failure patients in varying ejection fractions with and without diabetes, and its impact in a real-world clinical setting, remain underexplored.
methodsThis multicenter observational study, conducted in a real-world setting, from November 2022 to October 2023 in four specialized and tertiary care hospitals in Bangladesh. The study included 797 patients diagnosed with heart failure, irrespective of ejection fraction, who received empagliflozin at a dose of 10 mg daily over six months. The primary aim was to evaluate the efficacy and safety of empagliflozin in enhancing clinical, biochemical, and echocardiographic parameters in patients with heart failure across ejection fraction types, with or without diabetes.
resultsOf the 797 enrolled patients, 460 (57.7%) had diabetes. Significant improvements were observed in both diabetic and non-diabetic groups across primary and secondary outcomes. Empagliflozin therapy led to improvements in New York Heart Association (NYHA) functional class (p = 0.001), echocardiographic parameters such as left ventricular ejection fraction (LVEF) (p = 0.003), and N-terminal pro–B-type Natriuretic Peptide (NT-proBNP) levels (p < 0.001). Biochemical markers also showed positive changes, including a significant reduction in serum creatinine (p = 0.001) and improvements in estimated Glomerular Filtration Rate (eGFR) (p < 0.001). Subgroup analyses revealed that the therapeutic effects were consistent across different age groups, BMI categories, and longer duration of diabetes.
conclusionsEmpagliflozin significantly improved cardiovascular and renal outcomes in heart failure patients, regardless of diabetes status. These findings support the inclusion of empagliflozin in the management of heart failure in clinical practice, particularly for patients with coexisting diabetes or chronic kidney disease. Further large-scale, long-term studies are needed to confirm these results and assess sustained benefits. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.